Listen
ZALVISO (sufentanil), analgesic
NEUROLOGY - New route of administration
Opinions on drugs -
Posted on
Apr 25 2016
Reason for request
Inclusion
No clinical benefit demonstrated when compared with intravenous patient-controlled analgesia, in the treatment of acute moderate to severe post-operative pain in adult patients
- ZALVISO has Marketing Authorisation in the treatment of acute moderate to severe post-operative pain in adult patients.
- The ZALVISO administration device is designed to deliver a single sufentanil 15 micrograms sublingual tablet, on a patient-controlled as needed basis, with a minimum interval of 20 minutes between doses, over a maximum period of 72 hours. No benefit has been demonstrated by comparison with intravenous, patient-controlled analgesia.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
